TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A paper published in The Lancet Healthy Longevity argues that sarcopenia and age-related mobility loss should be understood as problems involving the whole motor system, including the brain, nerves and muscles. The authors propose changes to assessment and research, but say new tests have not yet been shown to outperform existing screening or improve outcomes.
A paper published in The Lancet Healthy Longevity argues that age-related weakness and mobility loss should be understood as problems of the whole motor system, not just shrinking muscles. The authors say the brain, spinal cord, nerves and their connections to muscle can all affect movement, and propose changes to how sarcopenia is assessed and studied.
The authors say clinical definitions of sarcopenia have already moved beyond muscle size: measures such as grip strength, walking speed and chair stands are used because they predict outcomes including falls and disability better than muscle mass alone. But, they argue, the explanation for weakness has not kept pace. Sarcopenia is still commonly framed as a muscle disease, with weakness treated as a consequence of muscle wasting.
The paper says muscle loss accounts for only a modest proportion of strength decline in older adults. People with similar amounts of muscle can have substantially different strength and mobility, the authors write. They also point to a contrast in research: interventions that increase muscle mass have not always produced comparable gains in everyday function, while exercise can improve strength and mobility without a measurable increase in muscle mass.
Instead, the authors describe age-related changes across the motor system: movement planning may slow, nerve signals may become less reliable or weaker, and balance and position sense can decline. They argue that tasks such as rising quickly from a chair depend on power and the nervous system’s ability to recruit muscle, not simply on how much muscle a person has.
A Broader View of Mobility Loss
The proposal could change what clinicians and researchers look for when an older person becomes weaker or slower. If muscle size is only part of the picture, assessments and treatments focused mainly on building muscle may miss other contributors to difficulty walking, standing or keeping balance. The authors suggest that clinicians also pay attention to chair-rise speed, unsteadiness, hand dexterity and changes in walking when a person is asked to talk at the same time.
The issue has practical importance because loss of mobility can threaten independence and increase the risk of falls. The Medical Xpress report cited Australian figures of 253,800 fall-related hospitalizations in 2024–25 and 6,722 deaths following falls in the preceding year. Those figures describe the scale of fall injuries; they do not show that the proposed motor-system approach would prevent them. The authors say the reframing could guide more targeted research and care, but its benefits have not yet been established.
The paper also raises medication review as part of care. Its authors say sedative and anticholinergic medicines can blunt motor drive and argue that reviewing such medicines should sit alongside strength training. This is a proposal for clinical consideration, not evidence that any particular medication should be stopped without professional advice.
Products Worth Considering
Hyperice Normatec 3 Leg Compression Boots – Standard Size
Bowflex SelectTech 840 Adjustable Kettlebell
Withings Sleep Under-Mattress Sleep Tracking Pad
As an affiliate, we earn on qualifying purchases.
How Sarcopenia Is Assessed
Sarcopenia refers to substantial loss of muscle, strength and physical function associated with aging. The Medical Xpress report says it affects up to 29% of older adults living in the community, with higher rates reported in hospital and residential-care settings and among people with multiple conditions or frailty. The condition is linked to frailty, disability and reduced independence.
Earlier in 2026, the Australian Journal of General Practice published a proposed algorithm to guide primary-care screening, assessment and management of poor muscle health, according to the report. The new paper, by Lucas B. R. Orssatto and colleagues, appeared in The Lancet Healthy Longevity under the title “Reframing sarcopenia as a disease of the ageing motor system.” It sets out a five-point agenda for international groups responsible for diagnostic criteria.
The debate is not whether muscle matters. The authors’ argument is that muscle measures alone do not explain the differences in strength and function seen among older adults, and that clinical descriptions should reflect the wider biology involved in movement.
“Reframing sarcopenia as a disease of the ageing motor system”
— Lucas B. R. Orssatto and co-authors, in their paper in The Lancet Healthy Longevity
Tests and Benefits Still Unproven
The authors acknowledge that the proposed assessment measures have not been shown to outperform existing screens on health outcomes or cost. The report also notes that specialist neuromuscular expertise is not equally available in primary care. It remains unclear which practical tests would be reliable and feasible for routine use, or whether adding them would lead to better treatment decisions.
The paper proposes a research and guideline agenda; it does not report a clinical trial demonstrating that the broader model prevents falls, restores mobility or preserves independence. The scale of benefit from changing diagnostic criteria, medication reviews or treatment strategies is therefore not yet known.
Validation Before Clinical Change
The authors call for investment in studies to validate practical tests, guidance that supports a staged approach to assessment, and trials that measure nerve as well as muscle. Those steps would help determine whether a broader evaluation can identify why an individual is weakening and whether it improves care compared with current screening.
For now, the paper presents a case for expanding research and clinical attention, rather than a proven replacement for existing practice. Any changes to an individual’s assessment or medicines remain matters for discussion with a qualified health professional.
Key Questions
What does the paper mean by the motor system?
It refers to the systems involved in producing movement, including the brain, spinal cord, nerves and muscles, along with the connections among them.
Does the paper say muscle loss is not involved in sarcopenia?
No. The authors argue that muscle loss is part of the picture but explains only a modest share of strength decline and does not account for all differences in mobility.
They suggest looking at how quickly a person rises from a chair, unsteadiness during sustained effort, hand dexterity and whether walking changes when conversation is added. These suggestions still need validation for routine use.
Has the proposed approach been shown to prevent falls?
No. The report says the proposed measures have not been shown to outperform existing screens on outcomes or cost. The paper calls for studies and trials; it does not establish that the approach prevents falls.
Source: rss
